Abstract
Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are B-cell malignancies that together account for an estimated 75,000 new cases in the United States annually. Many patients with these diseases are successfully treated with cytotoxic therapy; however, the addition of biologic therapy in the form of the anti-CD20 antibody rituximab has significantly improved the outcome of patients, particularly those with B-cell NHL. The success of this agent has led to the development of multiple other monoclonal antibodies directed at targets on lymphoma cells and these therapies are now in clinical trials to determine their utility in the treatment of patients with NHL and HL.
| Original language | English (US) |
|---|---|
| Title of host publication | Emerging Protein Biotherapeutics |
| Publisher | CRC Press |
| Pages | 223-245 |
| Number of pages | 23 |
| ISBN (Electronic) | 9781420063219 |
| ISBN (Print) | 1420063200, 9781420063202 |
| State | Published - Jan 1 2009 |
Keywords
- Hodgkin’s disease
- Monoclonal antibody
- Non-hodgkin lymphoma
ASJC Scopus subject areas
- General Pharmacology, Toxicology and Pharmaceutics
- General Biochemistry, Genetics and Molecular Biology
- General Medicine